CBD-based drug moves closer to authorisation in Europe
The Human Medicines Committee of the European Medicines Agency have recently granted a positive opinion regarding the use of cannabidiol (CBD) based drug Epidyolex (spelled as Epidiolex in the US) in two forms of epilepsy.
As part of their July meeting, the committee recommended marketing approval for the drug in Lennox Gastaut & Dravet Syndromes in patients over two years old who are already prescribed Clobazam (Frisium).